{"id":52477,"date":"2023-01-03T15:02:18","date_gmt":"2023-01-03T14:02:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/"},"modified":"2023-01-03T15:02:18","modified_gmt":"2023-01-03T14:02:18","slug":"yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/","title":{"rendered":"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%"},"content":{"rendered":"
\n

\nAuthorized Generic of Flector\u00ae<\/sup> Now Available<\/b>\n<\/p>\n

PARSIPPANY, N.J.–(BUSINESS WIRE)–Yaral Pharma Inc.<\/a>, the US generics subsidiary of IBSA<\/a>, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland today announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma\u2019s Flector\u00ae <\/sup>(diclofenac epolamine) topical system<\/i>. Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are excited to kick off the new year by launching the first of several products in our portfolio which includes authorized and complex generic medications,\u201d said Stephen Beckman, CEO, Yaral Pharma. \u201cLike Flector, Yaral Pharma\u2019s diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment backed by more than 30 years of clinical experience. We are pleased to offer patients an accessible and affordable product that offers targeted topical pain relief and look forward to expanding our product line across a range of therapeutic areas in the months ahead.\u201d\n<\/p>\n

\nYaral Pharma\u2019s diclofenac epolamine topical system 1.3% patch (NDC 82347-0405-5) is currently available to order. For questions about ordering, contact Yaral Pharma at 1-866-218-9009.\n<\/p>\n

\nYaral Pharma has begun commercializing IBSA Pharma\u2019s authorized generics and is poised to rapidly expand its product line organically through outside opportunities and external partnerships with a focus on oral solid dosage (OSD), complex and 505(b)2 products. The Company\u2019s current portfolio includes products in the therapeutic areas of pain and endocrinology with future expansion planned in the areas of rheumatology, fertility\/women’s health, dermatology\/dermo-aesthetic, and ophthalmology. For the latest updates on Yaral Pharma, visit www.yaral-pharma.com<\/a> or connect with us on LinkedIn<\/a>.\n<\/p>\n

\nProduct Information<\/b>\n<\/p>\n\n\n\n
\n

\nProduct<\/b>\n<\/p>\n<\/td>\n

\n

\nStrength<\/b>\n<\/p>\n<\/td>\n

\n

\nNDC #<\/b>\n<\/p>\n<\/td>\n

\n

\nPackage<\/b> Size<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDiclofenac epolamine topical system\n<\/p>\n<\/td>\n

\n

\n1.3%\n<\/p>\n<\/td>\n

\n

\n82347-0405-5\n<\/p>\n<\/td>\n

\n

\nOne Carton = 30 patches\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nTo order, please call Yaral Pharma at 1-866-218-9009.\n<\/p>\n

\nPlease refer to the full Prescribing Information, including Boxed Warning for diclofenac epolamine topical system, 1.3% <\/b>here<\/b><\/a>.<\/b>\n<\/p>\n

\nYou are encouraged to report suspected adverse reactions to Yaral Pharma by emailing MI@yaral-pharma.com<\/a> or calling 866-218-9009 or to the FDA by visiting http:\/\/www.fda.gov\/medwatch<\/a>.\n<\/p>\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n

\nWARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\nCardiovascular Thrombotic Events<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

    \n
  • \nNonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.\n<\/li>\n
  • \nDiclofenac epolamine topical system 1.3% is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.\n<\/li>\n<\/ul>\n

    \n\u00a0\n<\/p>\n

    \nGastrointestinal Bleeding, Ulceration, and Perforation<\/b>\n<\/p>\n

    \n\u00a0\n<\/p>\n

      \n
    • \nNSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and\/or GI bleeding are at greater risk for serious GI events.\n<\/li>\n<\/ul>\n<\/td>\n
\u00a0<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

About Authorized Generics<\/b>\n<\/p>\n

\nAccording to the U.S. Food and Drug Administration, the term \u201cauthorized generic\u201d drug is most commonly used to describe an approved brand name drug that is marketed without the brand name on its label. Other than the fact that it does not have the brand name on its label, it is the exact same drug product as the branded product. The product the patient receives is identical to the branded product, contains the same active and inactive ingredients, and is manufactured using the same process at a considerable cost savings.\n<\/p>\n

\nAbout Yaral Pharma<\/b>\n<\/p>\n

\nYaral Pharma Inc. (Parsippany, NJ) is the US generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they\u2019re cared for, Yaral Pharma is proud to offer the same values and expertise of its parent company to the US market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, Yaral Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service. For more information, visit www.yaral-pharma.com<\/a> or contact info@yaral-pharma.com<\/a> or 866-218-9009.\n<\/p>\n

\nFlector\u00ae<\/sup> is a registered trademark of IBSA Institut Biochimique S.A.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nDaina Basile
\n
Kovak-Likly Communications
\n
203-762-8833, dbasile@klcpr.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Authorized Generic of Flector\u00ae Now Available PARSIPPANY, N.J.–(BUSINESS WIRE)–Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland today announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma\u2019s Flector\u00ae (diclofenac epolamine) topical system. Diclofenac epolamine topical system 1.3% is a prescription … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52477","6":"format-standard","7":"category-industry"},"yoast_head":"\nYaral Pharma Launches Diclofenac Epolamine Topical System 1.3% - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3% - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Authorized Generic of Flector\u00ae Now Available PARSIPPANY, N.J.–(BUSINESS WIRE)–Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland today announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma\u2019s Flector\u00ae (diclofenac epolamine) topical system. Diclofenac epolamine topical system 1.3% is a prescription ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-03T14:02:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221230005209\/en\/1674498\/21\/Yaral_FullColor_RBG.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%\",\"datePublished\":\"2023-01-03T14:02:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/\"},\"wordCount\":716,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221230005209\\\/en\\\/1674498\\\/21\\\/Yaral_FullColor_RBG.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/\",\"name\":\"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3% - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221230005209\\\/en\\\/1674498\\\/21\\\/Yaral_FullColor_RBG.jpg\",\"datePublished\":\"2023-01-03T14:02:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221230005209\\\/en\\\/1674498\\\/21\\\/Yaral_FullColor_RBG.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221230005209\\\/en\\\/1674498\\\/21\\\/Yaral_FullColor_RBG.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3% - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/","og_locale":"en_US","og_type":"article","og_title":"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3% - Pharma Trend","og_description":"Authorized Generic of Flector\u00ae Now Available PARSIPPANY, N.J.–(BUSINESS WIRE)–Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland today announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma\u2019s Flector\u00ae (diclofenac epolamine) topical system. Diclofenac epolamine topical system 1.3% is a prescription ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-03T14:02:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221230005209\/en\/1674498\/21\/Yaral_FullColor_RBG.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%","datePublished":"2023-01-03T14:02:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/"},"wordCount":716,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221230005209\/en\/1674498\/21\/Yaral_FullColor_RBG.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/","url":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/","name":"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3% - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221230005209\/en\/1674498\/21\/Yaral_FullColor_RBG.jpg","datePublished":"2023-01-03T14:02:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221230005209\/en\/1674498\/21\/Yaral_FullColor_RBG.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221230005209\/en\/1674498\/21\/Yaral_FullColor_RBG.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/yaral-pharma-launches-diclofenac-epolamine-topical-system-1-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52477"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52477\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}